BMS will expand its NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems to train proprietary foundation models, building on nearly three years of NVIDIA collaboration.
Under its Predict First approach, BMS says AI-generated predictions inform the design of every small-molecule program and most large-molecule programs before bench work.
Trade press reported that Moderna showed Lucy, an internal machine-learning platform that runs closed-loop lab experiment cycles, at its 2026 Science Day.
AI-enabled tools across manufacturing, commercial and corporate functions
OtherDeployment
Sun Pharma's FY26 annual report says the company expanded the use of digital and AI-enabled tools across manufacturing, commercial and corporate functions to support planning, productivity and execution.
OpenFold-3 and other in-house AI models for drug discovery
AI drug discoveryDeployment
Daiichi Sankyo says it has introduced advanced AI models, including OpenFold-3, into its internal environment and provides them to researchers as cloud applications, adjusting models with the research organization so AI can be used in actual drug-discovery work.
Daiichi Sankyo says it has introduced AI agents into bioinformatics work and is using them to make exploration and analysis of life-science data more efficient and more advanced, while checking their usefulness on actual analysis work.
Natural-language AI search of clinical trial information
Clinical developmentDeployment
Daiichi Sankyo says that, on its integrated data analysis platform, it provides an environment in which employees who are not engineers or data scientists can search and analyze clinical-trial information in everyday language by incorporating AI functions.
Next-generation safety database with AI automation
Regulatory, medical writing and pharmacovigilanceAnnouncement
Daiichi Sankyo says that, going forward, it is renewing its safety database into a next-generation database that incorporates automation by AI, in order to make global pharmacovigilance operations more efficient and to strengthen analysis.
Image AI for liquid measurement in experimental equipment
OtherDeployment
As part of its smart research lab work, Daiichi Sankyo says it has built AI into experimental equipment so that liquid-volume measurement and checks of the boundary between liquids, previously done by eye, can be done automatically in real time.
Jazz's 2025 sustainability report says the company introduced MOMENTUM in 2025, a clinical trial toolbox for patient-representation insights. It says MOMENTUM draws on large language model technology to help teams design more representative trials and recruit patient populations that reflect true disease epidemiology.
Jazz's 2025 sustainability report says that in 2025 the company formally established an AI Council for cross-functional governance and oversight of AI use, and that it established AI Responsible Use Guidelines to define expectations and support consistent application.
Jazz's 2025 sustainability report says that in the fourth quarter of 2025 the company launched an enterprise-wide AI Literacy platform to build foundational capability across the workforce.
An in-silico trial platform built on Sanofi disease-biology models and clinical data. It is meant to predict safety, efficacy and trial outcomes to inform go/no-go decisions.
City A.M. reports that GSK's director of AI and machine learning told London Tech Week that agentic AI is already affecting every asset in the R&D pipeline and is a live operational tool.
Generative AI scan for patient-level treatment matching
Diagnostics and clinical decision supportType not stated
The same City A.M. report says GSK is using generative AI to scan internal and external datasets, including literature, bench results and clinical trials, to try to match a treatment to an individual patient.